Skip to main content

Advertisement

SpringerLink
Log in

The Bone-Building Action of the Parathyroid Hormone

Implications for the Treatment of Osteoporosis

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

As populations age in the world’s 7 major pharmaceutical markets, an increasing number of men and women, but especially women during their first postmenopausal decade, are falling victim to a bone disease that can result in hospitalisation, disability and death. This disease is osteoporosis. Indeed, by the year 2007, as many as 153 000 000 people will have experienced at least some significant osteopenia, if not osteoporosis. Although there are many different drugs, such as calcitonin, the bisphosphonates, estrogen and selective estrogen receptor modulators, that can slow or even stop further bone loss, there are currently few that can replace already lost bone by directly stimulating bone growth. However, a family of potent bone-building (or bone-anabolic) peptides is currently undergoing clinical development. These are the first-generation 84-amino acid native parathyroid hormone (PTH) and its 34- to 38-amino acid N terminal fragments, and the potent second-generation mini-PTHs. In this article, we briefly summarise what has so far been learned about how these molecules stimulate the production of new biomechanically strong bone in animals and humans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Marchand G. Commercial exploitation of parathyroid hormone therapy for the treatment of postmenopausal osteoporosis. In: Whitfield JF, Morley P, editors. Anabolic treatments for osteoporosis. Boca Raton (FL): CRC Press, 1998: 175–83

    Google Scholar 

  2. Sannes LJ. Osteoporosis market set to expand with new drug launches. In: Decision Resources Spectrum Series. Spectrum: therapies markets and emerging technologies. Waltham: Decision Resources, 1998

    Google Scholar 

  3. Stevenson JC, Lindsay RL, editors. Osteoporosis. London: Chapman and Hall Medical, 1998

    Google Scholar 

  4. Whitfield JF, Morley P, Willick GE. The parathyroid hormone: an unexpected bone builder for treating osteoporosis. Austin (TX): Landes Bioscience, 1998

    Google Scholar 

  5. Bauer E, Aub JC, Albright F. Studies of calcium and phosphorus metabolism: V. a study of the bone trabeculae as a readily available reserve supply of calcium. J Exp Med 1929; 49: 145–62

    Article  PubMed  CAS  Google Scholar 

  6. Péhu M, Policard A, Dufort A. L’Ostéopetrose ou maladie des os marmoréens. Presse Med 1931; 53: 999–1003

    Google Scholar 

  7. Selye H. On the stimulation of new bone-formation with parathyroid extract and irradiated ergosterol. Endocrinology 1932; 16: 547–58

    Article  CAS  Google Scholar 

  8. Dempster DW, Cosman F, Parisien M, et al. Anabolic action of parathyroid hormone. Endocr Rev 1993; 14: 690–709

    PubMed  CAS  Google Scholar 

  9. Reeve J. PTH: a future role in the management of osteoporosis? J Bone Miner Res 1996; 11: 440–5

    Article  PubMed  CAS  Google Scholar 

  10. Whitfield JF, Morley P, editors. Anabolic treatments for osteoporosis. Boca Raton (FL): CRC Press, 1997

    Google Scholar 

  11. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1998; 80: 3689–98

    Article  Google Scholar 

  12. Sharpe RM. The role oestrogen in the male. Trends Endocrinol Metab 1998; 9: 371–7

    Article  PubMed  CAS  Google Scholar 

  13. Vanderschueren D, Van Herck E, DeCoster R, et al. Aromatization of androgens is important for skeletal maintenance of aged male rats. Calcif Tissue Int 1996; 59: 179–83

    Article  PubMed  CAS  Google Scholar 

  14. World Health Organization (WHO). Assessment of fracture risk and its application to screening for osteoporosis [WHO Technical Report Series]. Geneva: WHO, 1994

    Google Scholar 

  15. Frost HM. Tetracycline-based histological analysis of bone remodelling. Calif Tissue Int 1969; 3: 211–37

    Article  CAS  Google Scholar 

  16. Martin TJ, Dempster DW. Bone structure and cellular activity. In: Stevenson JC, Lindsay R, editors. Osteoporosis. London: Chapman and Hall Medical, 1997: 1–28

    Google Scholar 

  17. Kameda T, Mano H, Yamada Y, et al. Calcium- sensing receptors in mature osteoclasts which are bone-resorbing cells. Biochem Biophys Res Commun 1998; 245: 419–22

    Article  PubMed  CAS  Google Scholar 

  18. Baron R, Ravesloot J-H, Neff L, et al. Cell and molecular biology of the osteoclast. In: Noda M, editor. Cellular and molecular biology of bone. San Diego (CA): Academic Press, 1993: 445–95

    Google Scholar 

  19. Zaidi A, Adebanjo OA, Moonga BS, et al. Emerging insights into the role of calcium ions in osteoclast regulation. J Bone Miner Res 1999; 14: 669–74

    Article  PubMed  CAS  Google Scholar 

  20. Gowen M, Stroup GB, Bradbeer KN, et al. An antagonist of the parathyroid cell Ca2+ receptor stimulates PTH secretion and bone turnover in osteopenic ovariectomized rats [abstract]. Bone 1998; 23: S163

    Article  Google Scholar 

  21. Eriksen EF, Axelrod DW, Melsen F. Bone histomorphometry. New York: Raven Press, 1994

    Google Scholar 

  22. Eriksen EF, Langdahl B, Klassen M. The cellular basis of osteoporosis. Spine: State Arts Revs 1994; 8: 23–62

    Google Scholar 

  23. Frost HM. Osteoporoses: their nature and therapeutic targets. In: Whitfield JF, Morley P, editors. Boca Raton (FL): CRC Press, 1998: 1–27

  24. Einhorn TA. Biomechanics of bone. In: Bilezekian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego (CA): Academic Press, 1996: 25–37

    Google Scholar 

  25. Hoyland JA, Neary J, Baris C, et al. Loss of osteocyte estrogen receptor expression in men with idiopathic osteoporosis [abstract]. Bone 1998; 22: 10S

    Google Scholar 

  26. Thomsen IS, Mosekilde L, Boyce RM, et al. Stochastic simulation of vertebral trabecular bone remodelling. Bone 1994; 15: 655–66

    Article  PubMed  CAS  Google Scholar 

  27. Dempster DW. Exploiting and bypassing the bone remodelling cycle to optimize the treatment of osteoporosis. J Bone Miner Res 1997; 12: 1152–4

    Article  PubMed  CAS  Google Scholar 

  28. Zecchi-Orlandini S, Formigli L, Tani A, et al. 17β-estradiol induces apoptosis in the proetseoclastic FLG 29.1 cell line. Biochem Biophys Res Commun 1999; 255: 680–5

    Article  PubMed  CAS  Google Scholar 

  29. Jilka RL. Cytokines, bone remodelling, and estrogen deficiency. Bone 1998; 23: 75–8

    Article  PubMed  CAS  Google Scholar 

  30. Martin TJ, Romas E, Gillespie MT. Interleukins in the control of osteoclast differentiation. Crit Rev Eukaryot Gene Expr 1998; 107–23

    Google Scholar 

  31. Pilbeam C, Rao Y, Alander C, et al. Downregulation of mRNA expression for the ‘decoy’ interleukin-1 receptor 2 by ovariectomy. J Bone Miner Res 1997; 12Suppl. 1: S433

    Google Scholar 

  32. Brandi ML, Hukkanen M, Umeda T, et al. Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc Natl Acad Sci U S A 1995; 92: 2954–8

    Article  PubMed  CAS  Google Scholar 

  33. Holliday LS, Dean AD, Kin RH, et al. Low NO concentrations inhibit osteoclast formation in mouse marrow cultures by a cGMP-dependent mechanism. Am J Physiol 1997; 272 (3 Pt 2): F283–91

    PubMed  CAS  Google Scholar 

  34. Tomkinson A, Gevers EF, Wit JM, et al. The role of estrogen in the control of rat osteocyte apoptosis. J Bone Miner Res 1998; 13: 1243–50

    Article  PubMed  CAS  Google Scholar 

  35. Nemere I, Farach-Carson MC. Membrane receptors for steroid hormones: a case for specific binding sites for vitamin D metabolites and estrogens. Biochem Biophys Res Commun 1998; 248: 443–9

    Article  PubMed  CAS  Google Scholar 

  36. Picotto G, Massheimer V, Boland R. Acute stimulation of intestinal calcium influx induced by 17β-estradiol via the cAMP messenger system. Mol Cell Endocrinol 1996; 119: 129–34

    Article  PubMed  CAS  Google Scholar 

  37. Salih MA, Sims SH, Kalu DN. Putative intestinal estrogen receptor: evidence for regional differences. Mol Cell Endocrinol 1996; 121: 47–55

    Article  PubMed  CAS  Google Scholar 

  38. Lindsay R. Estrogen and osteoporosis. In: Stevenson JC, Lindsay R, editors. London: Chapman and Hall Medical, 1998: 161–71

  39. Roodman GD. Advances in bone biology: the osteoclast. Endocr Rev 1996; 17: 308–32

    PubMed  CAS  Google Scholar 

  40. Shen Y, Li M, Wronski TJ. Calcitonin provides complete protection against cancellous bone loss in the femoral neck of ovariectomized rats. Calcif Tissue Int 1997; 60: 457–61

    Article  PubMed  CAS  Google Scholar 

  41. Fleisch H. Bisphosphonates in bone disease. New York: The Parthenon Publishing Group, 1997

    Google Scholar 

  42. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80–100

    Article  PubMed  CAS  Google Scholar 

  43. Hughes DE, Wright KE, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10: 1478–87

    Article  PubMed  CAS  Google Scholar 

  44. Bergwitz C, Gardella TJ, Flannery MR, et al. Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin. J Biol Chem 1996; 271: 26469–72

    Article  PubMed  CAS  Google Scholar 

  45. Iida-Klein A, Guo J, Takemura M, et al. Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor results in selective loss of PTH-stimulated phospholipase C activity. J Biol Chem 1997; 272: 6882–9

    Article  PubMed  CAS  Google Scholar 

  46. Friedman PA, Gesek FA, Morley P, et al. Cell-specific signalling and structure-activity relations of parathyroid hormone analogs in mouse kidney cells. Endocrinology 1999; 140: 301–9

    Article  PubMed  CAS  Google Scholar 

  47. Whitfield JF, Morley P, Willick G, et al. Stimulation of the growth of femoral trabecular bone in ovariectomized rats by the novel parathyroid hormone fragment hPTH-(1–31)NH2 (ostabolin). Calcif Tissue Int 1996; 58: 81–7

    Article  PubMed  CAS  Google Scholar 

  48. Whitfield JF, Morley P, Willick G, et al. Cyclization by a specific lactam increases the ability of human parathyroid hormone hPTH-(l–31)NH2 to stimulate bone growth in ovariectomized rats. J Bone Miner Res 1997; 12: 1246–52

    Article  PubMed  CAS  Google Scholar 

  49. Takasu H, Guo J, Bringhurst FR. Human and rat PTH/PTHrP display different signal selectivity for HPTH(1–31) and HPTH(l–30) in stably transformed LLC-PK1 cells [abstract]. J Bone Miner Res 1997; 12: S444

    Google Scholar 

  50. Whitfield JF, Isaacs RJ, MacLean S, et al. Stimulation of membrane-associated protein kinase-C activity in spleen lymphocytes by hPTH-(l–31)NH2, its lactam derivative, [Leu27]-cyclo(Glu22-Lys26)-hPTH-(l–31)NH2, and hPTH-(l–30)NH2. Cell Signal 1999; 11: 159–64

    Article  PubMed  CAS  Google Scholar 

  51. Singh MKT, Kunnel JG, Strieleman PJ, et al. Parathyroid hormone (PTH)-(l–34), [Nle8,18,Tyr34]PTH-(3–34) amide, and PTH-related peptide —(1–34) stimulate phosphatidylcholine hydrolysis in UMR-106 osteoblastic cells: comparison with effects of phorbol 12,13-dibutyrate. Endocrinology 1999; 140: 131–7

    Article  PubMed  CAS  Google Scholar 

  52. Takasu H, Guo J, Bringhurst FR. Dual signaling and the ligand selectivity of the human PTH/PTHrP receptor. J Bone Miner Res 1999; 14: 11–20

    Article  PubMed  CAS  Google Scholar 

  53. Mosekilde L. Osteoporosis: mechanisms and models. In: Whitfield JF, Morley P, editors. Anabolic treatments for osteoporosis. Boca Raton (FL): CRC Press, 1998: 31–81

    Google Scholar 

  54. Wronski TJ, Li M. PTH: skeletal effects in the ovariectomized rat model for postmenopausal bone loss. In: Whitfield JF, Morley P, editors. Boca Raton (FL): CRC Press: 59–81

  55. Walker D. The induction of osteopetrotic changes in hypophysectomized, thyroparathyroidectomized, and intact rats of various ages. Endocrinology 1971; 89: 1389–406

    Article  PubMed  CAS  Google Scholar 

  56. Whitfield JF, Morley P, Langille RM, et al. Adenylyl cyclaseactivating anabolic agents: parathyroid hormone and prostaglandins E. In: Whitfield JF, Morley P, editors. Anabolic treatments for osteoporosis. Boca Raton (FL): CRC Press: 109–49

  57. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1–34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. In press

  58. Pereira R, Canalis E. Parathyroid hormone induces mac25/insulin-like growth factor binding protein 7 expression in osteoblasts [abstract]. Bone 1998; 23; S566

    Google Scholar 

  59. Watson PH, Fraher LJ, Kiesel D, et al. Enhanced osteoblast development after continuous infusion of rhPTH-(1–84) in the rat. Bone 1999; 24: 89–94

    Article  PubMed  CAS  Google Scholar 

  60. Blair HC, Julian BA, Cao X, et al. Parathyroid hormone-regulated production of stem cell factor in human osteoblasts and osteoblast-like cells. Biochem Biophys Res Commun 1999; 255: 778–84

    Article  PubMed  CAS  Google Scholar 

  61. Gruber HE, Farley SM, Baylink DJ. Predictions on future diagnosis and treatment of osteoporosis: results and discussion of a recent opinion poll. Calcif Tissue Int 1995; 57: 83–5

    Article  PubMed  CAS  Google Scholar 

  62. Reeve J, Hesp R, Williams D, et al. Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. Lancet 1976; I: 1035–6

    Article  Google Scholar 

  63. Reeve J, Tregear GW, Parsons JA. Preliminary trial of low doses of human parathyroid hormone fragment 1–34 in treatment of osteoporosis. Clin Endocrinol 1976; 21: 469–77

    Google Scholar 

  64. Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid human fragment on trabecular bone in involutional osteoporosis: a multicenter trial. BMJ 1980; 280: 1340–4

    Article  PubMed  CAS  Google Scholar 

  65. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350: 550–5

    Article  PubMed  CAS  Google Scholar 

  66. Hesch RD, Busch U, Prokop M, et al. Increase of vertebral density by combination therapy with pulsatile 1–38 PTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 1989; 44: 176–80

    Article  PubMed  CAS  Google Scholar 

  67. Hodsman AB, Fraher LJ, Watson PH, et al. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in post-menopausal women with osteoporosis. J Clin Endocrinol Metab 1997; 82: 620–8

    Article  PubMed  CAS  Google Scholar 

  68. Finkelstein JS, Klibanski A, Schafer EH, et al. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994; 331: 1618–23

    Article  PubMed  CAS  Google Scholar 

  69. Neer R, Slovik D, Daly M, et al. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. In: Christiansen C, Overgaard K, editors. Osteoporosis. Copenhagen: Osteopress APS, 1991: 1314–7

    Google Scholar 

  70. Bradbeer JN, Arlot ME, Meunier PJ, et al. Treatment of osteoporosis with parathyroid peptide (hPTH-34) and oestrogen: increase in volume density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol 1997; 37: 282–9

    Article  Google Scholar 

  71. Hodsman AB, Fraher LJ, Watson PH. Parathyroid hormone: the clinical experience and prospects. In: Whitfield JF, Morley P, editors. Anabolic treatments for osteoporosis. Boca Raton (FL): CRC Press, 1997: 83–1

    Google Scholar 

  72. Hodsman AB, Fraher LJ, Ostbye T, et al. An evaluation of several biochemical markers of bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin in therapy of osteoporosis. J Clin Invest 1993; 91: 1138–48

    Article  PubMed  CAS  Google Scholar 

  73. Hodsman AB, Steer BM. Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 1993; 14: 523–7

    Article  PubMed  CAS  Google Scholar 

  74. Hodsman AB, Kiessel M, Watson PH, et al. Bone histomorphometric changes after 2 years of cyclic parathyroid hormone treatment in women with osteoporosis [abstract]. Bone 1998; 23: S631

    Article  Google Scholar 

  75. Cosman F, Nieves J, Woelfert L, et al. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 1998; 13: 1051–5

    Article  PubMed  CAS  Google Scholar 

  76. Hodsman AB, Drost D, Fraher LJ, et al. The addition of a raloxifene analog (LY117018) allows for reduced PTH(l–34) dosing during reversal of osteopenia in ovariectomized rats. J Bone Miner Res 1999; 14: 675–9

    Article  PubMed  CAS  Google Scholar 

  77. Hodsman AB, Watson PH, Drost D, et al. Assessment of maintenance therapy with reduced doses of PTH-(l–34) in combination with a raloxifene analogue (LY117018) following anabolic therapy in the ovariectomized rat. Bone 1999; 24: 451–5

    Article  PubMed  CAS  Google Scholar 

  78. Rittmaster RS, Bolognese M, Ettinger M, et al. Treatment of osteoporosis with parathyroid hormone followed by alendronate: bone density results [abstract]. Bone 1998; 23: S517

    Google Scholar 

  79. Delman PD, Vergnaud P, Arlot ME, et al. The anabolic effect of human PTH-(l–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate: is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodelling system? Bone 1995; 16: 603–10

    Article  Google Scholar 

  80. Whitfield JF, Morley P, Willick GE, et al. Stimulation of femoral trabecular bone growth by human parathyroid hormone (hPTH)-(1–30)NH2. Calcif Tissue Int. In press

  81. Mohan S, Kutilek S, Zhang C, et al. Evidence that PTH effects on bone formation may involve modulation of PKA pathway while its effects on bone resorption may involve modulation of PKC pathway in a mouse model [abstract]. Bone 1998; 23: S449

    Google Scholar 

  82. Fraher LJ, Avram R, Watson PH, et al. A comparison of the biochemical responses to 1–31 hPTH and -34 hPTH given to healthy humans by slow infusion. J Clin Endocrinol Metab. In press

  83. Whitfield JF. Calcium: cell cycle driver, differentiator and killer. Austin (TX): Landes Bioscience, 1997

    Google Scholar 

  84. Werner H, LeRoith D. The insulin-like growth factor receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. Crit Rev Oncog 1997; 8: 71–92

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Biological Sciences, National Research Council of Canada, Building M-54, Montréal Road Campus, Ottawa, Ontario, K1A 0R6, Canada

    James F. Whitfield, Paul Morley & Gordon E. Willick

Authors
  1. James F. Whitfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Morley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gordon E. Willick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James F. Whitfield.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whitfield, J.F., Morley, P. & Willick, G.E. The Bone-Building Action of the Parathyroid Hormone. Drugs Aging 15, 117–129 (1999). https://doi.org/10.2165/00002512-199915020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199915020-00005

Keywords

Search

Navigation